141 related articles for article (PubMed ID: 35395739)
1. Analysis on short-term change of macular function and the correlates after intravitreal conbercept for CRVO-ME.
Wang YC; Li RR; Cai Y; Wei ZY; Shao CL
BMC Ophthalmol; 2022 Apr; 22(1):162. PubMed ID: 35395739
[TBL] [Abstract][Full Text] [Related]
2. Predictors of visual recovery in patients with macular edema secondary to central retinal vein occlusion after treatment with Conbercept.
Zhang Q; Hou Y; Cao X; Zhang R; Liu Y; Wei C; Wu C; Mei L; Zhang P
BMC Ophthalmol; 2021 Nov; 21(1):402. PubMed ID: 34809591
[TBL] [Abstract][Full Text] [Related]
3. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
Tang F; Qin X; Lu J; Song P; Li M; Ma X
Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
[TBL] [Abstract][Full Text] [Related]
4. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Li F; Sun M; Guo J; Ma A; Zhao B
Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
[TBL] [Abstract][Full Text] [Related]
6. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Microvascular Structure Changes after Conbercept Treatment on Macular Edema Secondary to Retinal Vein Occlusion.
Song W; Jiao W; Li F; Ma A; Zhao B
Biomed Res Int; 2020; 2020():9046781. PubMed ID: 32685542
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
9. Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion.
Gardašević Topčić I; Šuštar M; Brecelj J; Hawlina M; Jaki Mekjavić P
Doc Ophthalmol; 2014 Aug; 129(1):27-38. PubMed ID: 24906869
[TBL] [Abstract][Full Text] [Related]
10. Clinical, anatomical, and electrophysiological assessments of the central retina following intravitreal bevacizumab for macular edema secondary to retinal vein occlusion.
Loukianou E; Brouzas D; Chatzistefanou K; Koutsandrea C
Int Ophthalmol; 2016 Feb; 36(1):21-36. PubMed ID: 25820576
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
12. One-year efficacy of intravitreal conbercept injection for macular oedema secondary to central retinal vein occlusion in Chinese patients.
Zeng HY; Liu Q; Li XX; Sun YX; Zhang ZJ
Eye (Lond); 2020 Aug; 34(8):1459-1464. PubMed ID: 32094473
[TBL] [Abstract][Full Text] [Related]
13. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
14. Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion.
Saishin Y; Ito Y; Fujikawa M; Sawada T; Ohji M
Jpn J Ophthalmol; 2017 Jan; 61(1):67-73. PubMed ID: 27660163
[TBL] [Abstract][Full Text] [Related]
15. Changes of focal macular and full-field electroretinograms after intravitreal aflibercept in patients with central retinal vein occlusion.
Nishimura T; Machida S; Hara Y
Doc Ophthalmol; 2020 Oct; 141(2):169-179. PubMed ID: 32215778
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series.
Braimah IZ; Agyabeng K; Amoaku WM
Int Ophthalmol; 2021 Jul; 41(7):2445-2453. PubMed ID: 33782846
[TBL] [Abstract][Full Text] [Related]
17. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data.
Chatziralli I; Theodossiadis G; Moschos MM; Mitropoulos P; Theodossiadis P
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1093-1100. PubMed ID: 28214955
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical efficacy of intravitreal ranibizumab with and without triamcinolone acetonide in macular edema secondary to central retinal vein occlusion.
Fan C; Wang Y; Ji Q; Zhao B; Xie J
Curr Eye Res; 2014 Sep; 39(9):938-43. PubMed ID: 24635755
[TBL] [Abstract][Full Text] [Related]
20. The Role of Serum Inflammation-Based Factors in Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion and Its Subtypes.
Rao J; Wu N; Qu X; Hu Y; Wu Y; Cheng Y; Yan L; Huang H; Li S; Shi L; Wu X
Ophthalmic Res; 2021; 64(2):237-245. PubMed ID: 32506058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
